Express Pharma

GSK wins $235 million from Teva in Coreg patent trial

110

A federal jury in Wilmington, Delaware found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug

A US jury has ordered Teva Pharmaceutical Industries to pay GlaxoSmithKline more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

A federal jury in Wilmington, Delaware found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure.

The jury rejected Teva’s contention that the patent was invalid. It awarded GSK $234.1 million in lost profits and said the drug company deserved an additional $1.4 million in royalties.

GSK in a statement said that it was pleased with the trial’s outcome. Teva said it was di